SCHEMBL6404748

SCHEMBL6404748

Cc1ccc(-n2c(S)nnc2CNc2ccc(F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
LMNA P02545 3/20 0.59
HTT P42858 1/20 0.59
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.43
AURKA O14965 1/20 0.42
ABL1 P00519 1/20 0.42
NTRK1 P04629 1/20 0.42
LCK P06239 1/20 0.42
CSF1R P07333 1/20 0.42
RET P07949 1/20 0.42
MET P08581 1/20 0.42
PDGFRB P09619 1/20 0.42
PIM1 P11309 1/20 0.42
PDGFRA P16234 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404661 0.87 KMT2A (0.51) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6410540 0.86 ALDH1A1 (0.53) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6411070 0.85 L3MBTL1 (0.62) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6404676 0.85 L3MBTL1 (0.62) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6403486 0.83 L3MBTL1 (0.49) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL8279472 0.78 AURKA (0.47) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6405215 0.78 GAA (0.62) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL6406630 0.78 GAA (0.62) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL5447310 0.76 L3MBTL1 (1.00) GAAL3MBTL1LMNAHTTALDH1A1
SCHEMBL5450663 0.74 GAA (0.77) GAAL3MBTL1LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281937-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281937-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders SCION PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders SCION PHARMACEUTICALS, INC. (US) 2007-08-30 US disclosed
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof AGRIUS GROUP, LLC. 2005-12-29 US disclosed
WO-2005087750-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281937-A1 Ion Channel Modulators CACNA1B, CACNA1C, TRPV1 GAA 1560/4885L3MBTL1 3558/4885LMNA 1903/4885
US-20070203194-A1 Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders CACNA1C, CACNA1D, CACNA1G GAA 2648/4885L3MBTL1 1169/4885LMNA 3778/4885
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof ABCG2, ATP5ME, DNTT GAA 85/4885L3MBTL1 2749/4885LMNA 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.